Gilead upped on HIV franchise; Merck downgraded on Keytruda LoE at Deutsche Bank
Deutsche Bank upgraded Gilead Sciences (NASDAQ:GILD) on Tuesday, citing the antiviral developer’s HIV treatment franchise, ...
Deutsche downgrades Merck ahead of Keytruda 2028 expiration
Deutsche Bank analyst James Shin downgraded Merck (MRK) to Hold from Buy with a price target of $105, down from $128. The firm believes the ...
Barron's8mon
Competitor to Merck's Keytruda Worries Some Investors
Investors in Merck don't seem pleased with a competitor cancer-treatment candidate outperforming Keytruda. Summit Therapeutics says its monotherapy ivonescimab outperformed pembrolizumab ...
Seeking Alpha25d
Merck, Eisai post mixed Phase 3 data for Keytruda/ Lenvima in GIT cancer
Merck (NYSE:MRK) and Esai (OTCPK:ESALF) (OTCPK:ESAIY) announced Friday a mixed outcome in their Phase 3 LEAP-015 trial, which was designed to evaluate MRK’s anti-PD-1 therapy Keytruda and the Ja ...
Business Insider1mon
Merck & Company: Strategic Shifts and Upcoming Catalysts Amidst Keytruda Challenges
Discover outperforming stocks and invest smarter with Top Smart ... Despite the lowered price target from $136 to $119 due to risks related to Keytruda’s loss-of-exclusivity and Medicare price ...